{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:52:51Z","timestamp":1788850371427,"version":"build-2803163510"},"reference-count":38,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T00:00:00Z","timestamp":1534204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Our aim was to describe trends in the prescription of domperidone for insufficient lactation in England, the characteristics of women prescribed it postpartum, and the impact of a 2014 European Medicines Agency (EMA) recommendation to restrict its use due to a potential increased risk of sudden cardiac death associated with its use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a population\u2010based cohort study with interrupted time series analysis using data from the Clinical Practice Research Datalink linked to Hospital Episode Statistics. We identified women with live births from 2002 to 2015, excluding those with nonlactation indications for domperidone (n\u00a0=\u00a0247\u00a0349). We evaluated trends in the prescription rate of domperidone in the 6\u00a0months postpartum and differences in this rate before and after the EMA recommendation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Domperidone was prescribed among 1438 deliveries at a rate of 1.24 per 100 person\u2010years. This rate increased from 0.56 to 2.1 per 100 person\u2010years between 2002\u20102004 and 2011\u20102013 (rate ratio: 3.8; 95% confidence interval [CI], 3.2\u20104.6). Prescribing decreased in level by 0.35 (95% CI, \u22120.86 to 0.16) per 100 person\u2010years immediately following the recommendation with little change in trend (0.003; 95% CI, \u22120.059 to 0.065 per 100 person\u2010years). Following the recommendation, prescription of doses &gt;30\u00a0mg and coprescription of drugs with a risk of torsade de pointes decreased. No arrhythmic events were observed among domperidone users.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although we observed an important increase in prescribing during the study period, domperidone remains infrequently prescribed postpartum in England. While overall prescribing changed little, some prescribing practices became more restricted following the EMA's recommendation.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4621","type":"journal-article","created":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T09:09:25Z","timestamp":1534237765000},"page":"1316-1324","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Domperidone for insufficient lactation in England 2002\u20102015: A drug utilization study with interrupted time series analysis"],"prefix":"10.1002","volume":"27","author":[{"given":"Azar","family":"Mehrabadi","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Biostatistics and Occupational Health McGill University  Montreal Quebec Canada"},{"name":"Centre for Clinical Epidemiology, Lady Davis Institute Jewish General Hospital  Montreal Quebec Canada"},{"name":"Research Institute of the McGill University Health Centre  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Reynier","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology, Lady Davis Institute Jewish General Hospital  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5981-8443","authenticated-orcid":false,"given":"Robert W.","family":"Platt","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics and Occupational Health McGill University  Montreal Quebec Canada"},{"name":"Centre for Clinical Epidemiology, Lady Davis Institute Jewish General Hospital  Montreal Quebec Canada"},{"name":"Research Institute of the McGill University Health Centre  Montreal Quebec Canada"},{"name":"Department of Pediatrics McGill University  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6055-0088","authenticated-orcid":false,"given":"Kristian B.","family":"Filion","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics and Occupational Health McGill University  Montreal Quebec Canada"},{"name":"Centre for Clinical Epidemiology, Lady Davis Institute Jewish General Hospital  Montreal Quebec Canada"},{"name":"Department of Medicine McGill University  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,8,14]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/11536840-000000000-00000"},{"key":"e_1_2_9_3_1","unstructured":"NICE.Breastfeeding problems. Last revised May 2014."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20150067"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0890334412459804"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0338-0"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3771"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2016"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12964"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4035"},{"key":"e_1_2_9_11_1","unstructured":"European Medicines Agency.Restrictions on the use of domperidone\u2010containing medicines.2014. Accessed 2017\u201303\u201027."},{"key":"e_1_2_9_12_1","unstructured":"Health Canada.Summary safety review\u2014domperidone\u2014serious abnormal heart rhythms and sudden death (cardiac arrest).2015."},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1862"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/11584970-000000000-00000"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1057\/hsq.2011.3"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.5.686.32205"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/21.3.299"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-12-113"},{"key":"e_1_2_9_20_1","unstructured":"European Medicines Agency.Assessment report: domperidone\u2010containing medicinal products.2014."},{"key":"e_1_2_9_21_1","unstructured":"U.S. Food and Drug Administration.FDA Talk Paper: FDA warns against women using unapproved drug domperidone to increase milk production.2004;https:\/\/www.fda.gov\/Drugs\/DrugSafety\/InformationbyDrugClass\/ucm173886.htm. Accessed 2017\u201305\u201023."},{"issue":"10","key":"e_1_2_9_22_1","first-page":"A1","article-title":"Domperidone: risks of cardiac side effects","volume":"7","author":"Medicines & Healthcare Products Regulatory Agency","year":"2014","journal-title":"Drug Saf Update"},{"key":"e_1_2_9_23_1","unstructured":"Medicines & Healthcare products Regulatory Agency.Motilium 10 10mg tablets and motilium instants10mg\u2014changed to prescription\u2010only medicine.Class 2 medicinesrecall Vol 72014."},{"key":"e_1_2_9_24_1","unstructured":"WoosleyR RomeroK.QTdrugs list.http:\/\/www.crediblemeds.org. Accessed October 13 2016."},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-014-0215-z"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00321-8"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1983.03330370053031"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acap.2013.08.002"},{"issue":"8","key":"e_1_2_9_29_1","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jclinepi.2014.12.018","article-title":"Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations","volume":"68","author":"Jandoc R","journal-title":"J Clin Epidemiol"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3642"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128312"},{"issue":"9","key":"e_1_2_9_32_1","first-page":"952","article-title":"Health Canada advisory on domperidone should I avoid prescribing domperidone to women to increase milk production [corrected]?","volume":"58","author":"Bozzo P","year":"2012","journal-title":"Can Family Phys Medecin de Famille Canadien"},{"key":"e_1_2_9_33_1","unstructured":"FlandersD LoweA KramerM et al.A consensus statement on the use of domperidone to support lactation. May 11 2012;http:\/\/www.slideshare.net\/carmendomperidona\/domperidone\u2010consensus\u2010statementmay112012\u201016342209."},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/0890334416680176"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-3441"},{"issue":"1","key":"e_1_2_9_36_1","first-page":"17","article-title":"Effect of domperidone on milk production in mothers of premature newborns: a randomized, double\u2010blind, placebo\u2010controlled trial","volume":"164","author":"Silva OP","year":"2001","journal-title":"CMAJ"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01024-7"},{"key":"e_1_2_9_38_1","volume-title":"Breastfeeding trends in Canada. Vol Catalogue no. 82\u2013624\u2010X: Statistics Canada","author":"Gionet L","year":"2013"},{"key":"e_1_2_9_39_1","unstructured":"McAndrewF ThompsonJ FellowsL LargeA SpeedM RenfrewMJ.Infant Feeding Survey 2010.Health and Social Care Information Centre;2012."}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4621","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4621","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T17:27:28Z","timestamp":1694798848000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,14]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1002\/pds.4621"],"URL":"https:\/\/doi.org\/10.1002\/pds.4621","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,14]]},"assertion":[{"value":"2018-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}